MedPath

Vitamin D and Preeclampsia

Completed
Conditions
Vitamin D Deficiency Defined as Serum 25OHD < 75 Nmol/l or 30ng/ml
Preeclampsia
Neonatal Hypercalcemia
Pregnancy
Registration Number
NCT01648842
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Brief Summary

Hypothesis : Vitamin D serum concentration is decreased in the first trimester in pregnant women who will develop preeclampsia in the second or third trimester compare to a control group Primary purpose : To determine the vitamin D status in the first trimester in a large population of french pregnant women in order to evaluate the importance of the vitamin D deficiency in France and correlate this deficiency with preeclampsia

Detailed Description

Primary purpose : To compare the vitamin D (25OHD) status, in the first trimester, in a group of patients with preeclampsia and a group of pregnant women without preeclampsia.

Secondary purpose : (i)To compare the vitamin D status in the third trimester in a group of patients with preeclampsia and a group of pregnant women without preeclampsia. (ii) To evaluate the deficit un vitamin D in a population of pregnant women in the parisian area. (iii) To evaluate the calcemia of the newborns after maternal systematic oral intake of vitamin D 100000U at 28 weeks Methodology : Multicenter (6 centers), Cohort, Nested case-control study Protocol : 4500 patients will be recruited. A blood sample will be performed : in the first trimester (11-14 weeks), in the third trimester (28-40 weeks), and cord blood. For each patient with preeclampsia, 4 controls will be taken from the cohort and matched by parity, race/ethnicity, maternal age, season, BMI. The serum concentration of 25OHD will be measured in all samples.A dosage of 25OHD will be performed in 1000 women from the initial cohort in order to calculate the prevalence of vitamin D deficiency.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
3173
Inclusion Criteria
  • Pregnant woman
  • First trimester
  • Singleton
  • Affiliated to Social security policy
  • Woman who gave informed consent
Exclusion Criteria
  • Hypercalcemia (>2.65 mmol/l) or any other phosphocalcic disease
  • Hypertension (>140/90) from the first trimester
  • Renal insufficiency (creatinine > 120µmol/l)
  • Bone disease (osteogenesis imperfecta...)
  • Lithium therapy
  • Bowel malabsorption
  • Kidney stones

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Vitamin D (25OHD) status in the first trimester11-14 (+6) weeks of amenorrhea

To compare the vitamin D (25OHD) status, in the first trimester, in a group of patients with preeclampsia and a group of pregnant women without preeclampsia

Secondary Outcome Measures
NameTimeMethod
Deficit un vitamin D11-14 (+6) weeks of amenorrhea

To evaluate the deficit un vitamin D in a population of pregnant women in the parisian area

Vitamin D status in the third trimester28-40 weeks of amenorrhea

To compare the vitamin D status in the third trimester in a group of patients with preeclampsia and a group of pregnant women without preeclampsia

Calcemia of the newborns1 day (At the moment of the Guthrie test)

To evaluate the calcemia of the newborns after maternal systematic oral intake of vitamin D

Trial Locations

Locations (1)

Antoine Béclère Hospital

🇫🇷

Clamart, France

© Copyright 2025. All Rights Reserved by MedPath